FDA Submission Update for SCOMARA (Sirolimus) by AFT Pharmaceuticals
AFT Pharmaceuticals has submitted New Drug Application (NDA) for SCOMARA, an sirolimus-based therapy.
Asset / Drug
Drug and asset intelligence for SCOMARA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
mTOR Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.